| Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ... Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011 | 562 | 2011 |
| SAbDab: the structural antibody database J Dunbar, K Krawczyk, J Leem, T Baker, A Fuchs, G Georges, J Shi, ... Nucleic acids research 42 (D1), D1140-D1146, 2014 | 545 | 2014 |
| Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ... MAbs 5 (1), 22-33, 2013 | 383 | 2013 |
| Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ... Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011 | 299 | 2011 |
| ABodyBuilder: Automated antibody structure prediction with data–driven accuracy estimation J Leem, J Dunbar, G Georges, J Shi, CM Deane MAbs 8 (7), 1259-1268, 2016 | 222 | 2016 |
| SAbPred: a structure-based antibody prediction server J Dunbar, K Krawczyk, J Leem, C Marks, J Nowak, C Regep, G Georges, ... Nucleic acids research 44 (W1), W474-W478, 2016 | 206 | 2016 |
| ImmuneBuilder: Deep-Learning models for predicting the structures of immune proteins B Abanades, WK Wong, F Boyles, G Georges, A Bujotzek, CM Deane Communications Biology 6 (1), 575, 2023 | 139 | 2023 |
| ABlooper: fast accurate antibody CDR loop structure prediction with accuracy estimation B Abanades, G Georges, A Bujotzek, CM Deane Bioinformatics 38 (7), 1877-1880, 2022 | 126 | 2022 |
| The emerging role of new protein scaffold-based agents for treatment of cancer UH Weidle, J Auer, U Brinkmann, GUY Georges, G Tiefenthaler Cancer genomics & proteomics 10 (4), 155-168, 2013 | 122 | 2013 |
| The intriguing options of multispecific antibody formats for treatment of cancer UH Weidle, G Tiefenthaler, EH Weiss, G Georges, U Brinkmann Cancer genomics & proteomics 10 (1), 1-18, 2013 | 113 | 2013 |
| Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer UH Weidle, G Tiefenthaler, C Schiller, EH Weiss, GUY Georges, ... Cancer genomics & proteomics 11 (1), 25-38, 2014 | 111 | 2014 |
| DNA-encoded library-derived DDR1 inhibitor prevents fibrosis and renal function loss in a genetic mouse model of Alport syndrome H Richter, AL Satz, M Bedoucha, B Buettelmann, AC Petersen, ... ACS chemical biology 14 (1), 37-49, 2018 | 104 | 2018 |
| Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase ME Prime, SM Courtney, FA Brookfield, RW Marston, V Walker, J Warne, ... Journal of medicinal chemistry 54 (1), 312-319, 2011 | 103 | 2011 |
| The H3 loop of antibodies shows unique structural characteristics C Regep, G Georges, J Shi, B Popovic, CM Deane Proteins: Structure, Function, and Bioinformatics 85 (7), 1311-1318, 2017 | 100 | 2017 |
| Bispecific digoxigenin-binding antibodies for targeted payload delivery S Metz, AK Haas, K Daub, R Croasdale, J Stracke, W Lau, G Georges, ... Proceedings of the National Academy of Sciences 108 (20), 8194-8199, 2011 | 100 | 2011 |
| High thermostability and lack of cooperative DNA binding distinguish the p63 core domain from the homologous tumor suppressor p53 C Klein, G Georges, KP Kunkele, R Huber, RA Engh, S Hansen Journal of Biological Chemistry 276 (40), 37390-37401, 2001 | 92 | 2001 |
| Bispecific anti-VEGF/anti-ANG-2 antibodies M Baehner, U Brinkmann, G Georges, RA Griep, S Imhof-Jung, A Kavlie, ... US Patent 8,268,314, 2012 | 90 | 2012 |
| Format and geometries matter: Structure-based design defines the functionality of bispecific antibodies S Dickopf, GJ Georges, U Brinkmann Computational and structural biotechnology journal 18, 1221-1227, 2020 | 85 | 2020 |
| Proteases as activators for cytotoxic prodrugs in antitumor therapy UH Weidle, G Tiefenthaler, G Georges Cancer genomics & proteomics 11 (2), 67-79, 2014 | 77 | 2014 |
| A pentacyclic aurora kinase inhibitor (AKI-001) with high in vivo potency and oral bioavailability TE Rawson, M Rüth, E Blackwood, D Burdick, L Corson, J Dotson, ... Journal of medicinal chemistry 51 (15), 4465-4475, 2008 | 69 | 2008 |
